140
Participants
Start Date
October 4, 2019
Primary Completion Date
September 9, 2020
Study Completion Date
October 11, 2021
Etrasimod 1 mg
Etrasimod 1 mg tablet taken by mouth, once daily
Etrasimod 2 mg
Etrasimod 2 mg tablet taken by mouth, once daily.
Etrasimod matching placebo
Etrasimod matching placebo tablet by mouth, once daily.
Premier Specialists PTY LTD, Kogarah
Sinclair Dermatology, East Melbourne
Greenwich Village Dermatology, New York
Clinical Research Partners, LLC, Richmond
Alliance for Multispecialty Research, Norfolk
Spartanburg Medical Research, Spartanburg
Rophe Adult and Pediatric Medicine/SKYCRNG, Union City
Aby's New Generation Research, Inc., Hialeah
Skin Care Research, LLC, Hollywood
Advanced Research Institute of Miami LLC, Homestead
Amber Pediatrics Research, LLC, Homestead
Amber Clinical Research, LLC, Miami Shores
South Miami Medical & Research Group. Inc, Miami
Prohealth Research Center, Doral
Amber Pediatrics Research, LLC, Miami
Skin Research of South Florida, Miami
Clinical Research of West Florida, Inc., Tampa
IMA Clinical Research, LLC, St. Petersburg
Clinical Research of West Florida, Clearwater
Quinn Healthcare/SKYCRNG, Ridgeland
Skin Sciences PLLC, Louisville
Health Concepts, Rapid City
Quality Clinical Research Inc, Omaha
Modern Research Associates, PLLC, Dallas
FMC Science, Lampasas
Gadolin Research, Beaumont
FMC Science, Georgetown
Noble Clinical Research, Tucson
Excel Clinical Research, Las Vegas
ADVA Clinical Research, Inc, Inglewood
Hope Clinical Research, Canoga Park
Providence Clinical Research, North Hollywood
TCR Medical Corporation, San Diego
Marvel Research LLC, Huntington Beach
First OC Dermatology, Fountain Valley
ODRC Enterprises, LLC dba Oregon Dermatology and Research Center, Portland
Premier Clinical Research, Spokane
Diex Recherche Sherbrooke Inc., Sherbrooke
Lead Sponsor
Arena Pharmaceuticals
INDUSTRY